Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Yul Hwangbo  (Hwangbo Y) 8 Articles
Thyroid
Seaweed and Iodine Intakes and SLC5A5 rs77277498 in Relation to Thyroid Cancer
Tung Hoang, Eun Kyung Lee, Jeonghee Lee, Yul Hwangbo, Jeongseon Kim
Endocrinol Metab. 2022;37(3):513-523.   Published online May 24, 2022
DOI: https://doi.org/10.3803/EnM.2021.1306
  • 2,998 View
  • 134 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
This study aims to elucidate the associations among dietary seaweed (gim and miyeok/dashima) and iodine intakes, the rs77277498 polymorphism of the SLC5A5 gene codifying the sodium/iodine symporter, and thyroid cancer risk in a Korean population.
Methods
We conducted a case-control study of 117 thyroid cancer cases and 173 controls who participated in the Cancer Screenee Cohort between 2002 and 2014 at the National Cancer Center, Korea. The amount of seaweed and iodine consumption (g/day) was estimated using the residual energy adjustment method. We calculated odds ratios (ORs) and their 95% confidence intervals (CIs) using a multivariable logistic regression model for the separate and combined effect of dietary iodine-based intake and SLC5A5 polymorphism (rs77277498, C>G) on thyroid cancer.
Results
Dietary gim and iodine intakes were inversely associated with thyroid cancer, with ORs of 0.50 (95% CI, 0.30 to 0.83) and 0.57 (95% CI, 0.35 to 0.95), respectively, whereas the associations for dietary miyeok/dashima and total seaweed intakes were not significant. However, compared with individuals carrying the C/C genotype of the rs77277498 polymorphism with a low intake of all dietary factors, those carrying the G allele with a high intake had a lower risk of thyroid cancer, with ORs of 0.25 (95% CI, 0.10 to 0.56), 0.31 (95% CI, 0.12 to 0.77), 0.26 (95% CI, 0.10 to 0.62), and 0.30 (95% CI, 0.12 to 0.73) for the consumption of gim, miyeok/dashima, total seaweed, and iodine, respectively.
Conclusion
In summary, our results supported the evidence of the protective effects of dietary gim and iodine intake against thyroid cancer risk, and this association can be strengthened by SLC5A5 rs77277498 genotypes.

Citations

Citations to this article as recorded by  
  • Iodine nutrition and papillary thyroid cancer
    Xueqi Zhang, Fan Zhang, Qiuxian Li, Chuyao Feng, Weiping Teng
    Frontiers in Nutrition.2022;[Epub]     CrossRef
Close layer
Clinical Study
A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol
Eun Kyung Lee, You Jin Lee, Young Joo Park, Jae Hoon Moon, Ka Hee Yi, Koon Soon Kim, Joo Hee Lee, Sun Wook Cho, Jungnam Joo, Yul Hwangbo, Sujeong Go, Do Joon Park
Endocrinol Metab. 2020;35(3):571-577.   Published online September 22, 2020
DOI: https://doi.org/10.3803/EnM.2020.681
  • 4,442 View
  • 114 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Radioactive iodine (RAI) remnant ablation is recommended in patients with papillary thyroid cancer (PTC) and extrathyroidal extension or central lymph node metastasis. However, there exists little evidence about the necessity of remnant ablation in PTC patients with low- to intermediate-risk, those have been increasing in recent decades.
Methods
This multicenter, prospective, non-randomized, parallel group clinical trial will enroll 310 eligible patients with low- to intermediate-risk of thyroid cancer. Inclusion criteria are patients who recently underwent total thyroidectomy for PTC with 3 or less tumors of size 1≤ to ≤2 cm with no microscopic extension and N0/x, or size ≤2 cm with microscopic extension and/or N1a (number of lymph node ≤3, size of tumor foci ≤0.2 cm, and lymph node ratio <0.4). Patients choose to undergo RAI ablation (131I, dose 1.1 GBq) or diagnostic whole-body scan (DxWBS) (131I or 123I, dose 0.074 to 0.222 GBq), followed by subsequent measurement of stimulated thyroglobulin (sTg) within 1 year. Survey for quality of life (QOL) will be performed at baseline and at 1 year after follow-up. The total enrollment period is 5 years, and patients will be followed up for 1 year. The primary endpoint is the non-inferiority of surgery alone to surgery with ablation in terms of biochemical remission (BCR) rate (sTg ≤2 ng/mL) without evidence of structural recurrence. The secondary endpoint was the difference of QOL.
Conclusion
This study will evaluate whether surgery alone achieves similar BCR and improved QOL compared to RAI ablation in patients with low- to intermediate-risk PTC within 1 year.
Close layer
Miscellaneous
Diagnosis and Treatment of Growth Hormone Deficiency: A Position Statement from Korean Endocrine Society and Korean Society of Pediatric Endocrinology
Jung Hee Kim, Hyun Wook Chae, Sang Ouk Chin, Cheol Ryong Ku, Kyeong Hye Park, Dong Jun Lim, Kwang Joon Kim, Jung Soo Lim, Gyuri Kim, Yun Mi Choi, Seong Hee Ahn, Min Ji Jeon, Yul Hwangbo, Ju Hee Lee, Bu Kyung Kim, Yong Jun Choi, Kyung Ae Lee, Seong-Su Moon, Hwa Young Ahn, Hoon Sung Choi, Sang Mo Hong, Dong Yeob Shin, Ji A Seo, Se Hwa Kim, Seungjoon Oh, Sung Hoon Yu, Byung Joon Kim, Choong Ho Shin, Sung-Woon Kim, Chong Hwa Kim, Eun Jig Lee
Endocrinol Metab. 2020;35(2):272-287.   Published online June 24, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.2.272
  • 8,870 View
  • 404 Download
  • 12 Web of Science
  • 15 Crossref
AbstractAbstract PDFPubReader   ePub   
Growth hormone (GH) deficiency is caused by congenital or acquired causes and occurs in childhood or adulthood. GH replacement therapy brings benefits to body composition, exercise capacity, skeletal health, cardiovascular outcomes, and quality of life. Before initiating GH replacement, GH deficiency should be confirmed through proper stimulation tests, and in cases with proven genetic causes or structural lesions, repeated GH stimulation testing is not necessary. The dosing regimen of GH replacement therapy should be individualized, with the goal of minimizing side effects and maximizing clinical improvements. The Korean Endocrine Society and the Korean Society of Pediatric Endocrinology have developed a position statement on the diagnosis and treatment of GH deficiency. This position statement is based on a systematic review of evidence and expert opinions.

Citations

Citations to this article as recorded by  
  • Once-Weekly Somapacitan as an Alternative Management of Growth Hormone Deficiency in Prepubertal Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trial
    Ghina Tsurayya, Cut Alifiya Nazhifah, Muhammad Rahmat Pirwanja, Putri Oktaviani Zulfa, Muhammad Raihan Ramadhan Tatroman, Fajar Fakri, Muhammad Iqhrammullah
    Children.2024; 11(2): 227.     CrossRef
  • Evaluation of Adult Height in Patients with Non-Permanent Idiopathic GH Deficiency
    Agnese Murianni, Anna Lussu, Chiara Guzzetti, Anastasia Ibba, Letizia Casula, Mariacarolina Salerno, Marco Cappa, Sandro Loche
    Endocrines.2023; 4(1): 169.     CrossRef
  • The effect of hypothalamic involvement and growth hormone treatment on cardiovascular risk factors during the transition period in patients with childhood-onset craniopharyngioma
    Sang Hee Park, Yun Jeong Lee, Jung-Eun Cheon, Choong Ho Shin, Hae Woon Jung, Young Ah Lee
    Annals of Pediatric Endocrinology & Metabolism.2023; 28(2): 107.     CrossRef
  • Continuous Glucose Monitoring: A Possible Aid for Detecting Hypoglycemic Events during Insulin Tolerance Tests
    Soo Yeun Sim, Moon Bae Ahn
    Sensors.2023; 23(15): 6892.     CrossRef
  • The risk patients with AGHD have of developing CVD
    Eisha Javed, Maha Zehra, Naz Elahi
    International Journal of Cardiology Cardiovascular Risk and Prevention.2023; 19: 200221.     CrossRef
  • Diagnosis of GH Deficiency Without GH Stimulation Tests
    Anastasia Ibba, Sandro Loche
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Metabolic Impacts of Discontinuation and Resumption of Recombinant Human Growth Hormone Treatment during the Transition Period in Patients with Childhood-Onset Growth Hormone Deficiency
    Yun Jeong Lee, Yunha Choi, Han-Wook Yoo, Young Ah Lee, Choong Ho Shin, Han Saem Choi, Ho-Seong Kim, Jae Hyun Kim, Jung Eun Moon, Cheol Woo Ko, Moon Bae Ahn, Byung-Kyu Suh, Jin-Ho Choi
    Endocrinology and Metabolism.2022; 37(2): 359.     CrossRef
  • A Radiomics-Based Model with the Potential to Differentiate Growth Hormone Deficiency and Idiopathic Short Stature on Sella MRI
    Taeyoun Lee, Kyungchul Song, Beomseok Sohn, Jihwan Eom, Sung Soo Ahn, Ho-Seong Kim, Seung-Koo Lee
    Yonsei Medical Journal.2022; 63(9): 856.     CrossRef
  • Phenotypic spectrum of patients with mutations in CHD7: clinical implications of endocrinological findings
    Ja Hye Kim, Yunha Choi, Soojin Hwang, Gu-Hwan Kim, Han-Wook Yoo, Jin-Ho Choi
    Endocrine Connections.2022;[Epub]     CrossRef
  • Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
    Hyemi Kwon, Eun Roh, Chang Ho Ahn, Hee Kyung Kim, Cheol Ryong Ku, Kyong Yeun Jung, Ju Hee Lee, Eun Heui Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Jun Sung Moon, Jin Hwa Kim, Mi-kyung Kim
    Endocrinology and Metabolism.2022; 37(6): 839.     CrossRef
  • Laron syndrome: clinic, diagnostics (а clinical case)
    P.M. Lіashuk, R.P. Lіashuk, N.I. Stankova, M.B. Kudina
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2022; 18(3): 193.     CrossRef
  • Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force
    Eu Jeong Ku, Kyoung Jin Kim, Jung Hee Kim, Mi Kyung Kim, Chang Ho Ahn, Kyung Ae Lee, Seung Hun Lee, You-Bin Lee, Kyeong Hye Park, Yun Mi Choi, Namki Hong, A Ram Hong, Sang-Wook Kang, Byung Kwan Park, Moon-Woo Seong, Myungshin Kim, Kyeong Cheon Jung, Chan
    Endocrinology and Metabolism.2021; 36(2): 322.     CrossRef
  • Asian Conference on Tumor Ablation Guidelines for Adrenal Tumor Ablation
    Byung Kwan Park, Masashi Fujimori, Shu-Huei Shen, Uei Pua
    Endocrinology and Metabolism.2021; 36(3): 553.     CrossRef
  • Asian Conference on Tumor Ablation guidelines for renal cell carcinoma
    Byung Kwan Park, Shu-Huei Shen, Masashi Fujimori, Yi Wang
    Investigative and Clinical Urology.2021; 62(4): 378.     CrossRef
  • Diagnosis and Treatment of Adult Growth Hormone Deficiency
    Jung Hee Kim
    The Korean Journal of Medicine.2021; 96(5): 400.     CrossRef
Close layer
Miscellaneous
Corrigendum: Author's Name Correction. Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro)
Jae Hoon Moon, Ji-hoon Kim, Eun Kyung Lee, Kyu Eun Lee, Sung Hye Kong, Yeo Koon Kim, Woo-Jin Jeong, Chang Yoon Lee, Roh-Eul Yoo, Yul Hwangbo, Young Shin Song, Min Joo Kim, Sun Wook Cho, Su-jin Kim, Eun-Jae Chung, June Young Choi, Chang Hwan Ryu, You Jin Lee, Jeong Hun Hah, Yuh-Seog Jung, Junsun Ryu, Yunji Hwang, Sue K. Park, Ho Kyung Sung, Ka Hee Yi, Do Joon Park, Young Joo Park
Endocrinol Metab. 2018;33(3):427.   Published online August 14, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.3.427
  • 3,311 View
  • 46 Download
  • 2 Web of Science
  • 2 Crossref
PDFPubReader   ePub   

Citations

Citations to this article as recorded by  
  • Invasiveness and Metastatic Aggressiveness in Small Differentiated Thyroid Cancers: Demography of Small Papillary Thyroid Carcinomas in the Swedish Population
    Haytham Bayadsi, Martin Bergman, Malin Sund, Joakim Hennings
    World Journal of Surgery.2020; 44(2): 461.     CrossRef
  • Clinical and pathologic predictors of lymph node metastasis in papillary thyroid microcarcinomas
    Ling Zhao, Xiaoya Sun, Yukun Luo, Fulin Wang, Zhaohui Lyu
    Annals of Diagnostic Pathology.2020; 49: 151647.     CrossRef
Close layer
Thyroid
Genome-Wide Association Studies of Autoimmune Thyroid Diseases, Thyroid Function, and Thyroid Cancer
Yul Hwangbo, Young Joo Park
Endocrinol Metab. 2018;33(2):175-184.   Published online June 21, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.2.175
  • 7,632 View
  • 130 Download
  • 55 Web of Science
  • 54 Crossref
AbstractAbstract PDFPubReader   ePub   

Thyroid diseases, including autoimmune thyroid diseases and thyroid cancer, are known to have high heritability. Family and twin studies have indicated that genetics plays a major role in the development of thyroid diseases. Thyroid function, represented by thyroid stimulating hormone (TSH) and free thyroxine (T4), is also known to be partly genetically determined. Before the era of genome-wide association studies (GWAS), the ability to identify genes responsible for susceptibility to thyroid disease was limited. Over the past decade, GWAS have been used to identify genes involved in many complex diseases, including various phenotypes of the thyroid gland. In GWAS of autoimmune thyroid diseases, many susceptibility loci associated with autoimmunity (human leukocyte antigen [HLA], protein tyrosine phosphatase, non-receptor type 22 [PTPN22], cytotoxic T-lymphocyte associated protein 4 [CTLA4], and interleukin 2 receptor subunit alpha [IL2RA]) or thyroid-specific genes (thyroid stimulating hormone receptor [TSHR] and forkhead box E1 [FOXE1]) have been identified. Regarding thyroid function, many susceptibility loci for levels of TSH and free T4 have been identified through genome-wide analyses. In GWAS of differentiated thyroid cancer, associations at FOXE1, MAP3K12 binding inhibitory protein 1 (MBIP)-NK2 homeobox 1 (NKX2-1), disrupted in renal carcinoma 3 (DIRC3), neuregulin 1 (NRG1), and pecanex-like 2 (PCNXL2) have been commonly identified in people of European and Korean ancestry, and many other susceptibility loci have been found in specific populations. Through GWAS of various thyroid-related phenotypes, many susceptibility loci have been found, providing insights into the pathogenesis of thyroid diseases and disease co-clustering within families and individuals.

Citations

Citations to this article as recorded by  
  • A new, all‐encompassing aetiology of type 1 diabetes
    Piet C. de Groen
    Immunology.2024; 171(1): 77.     CrossRef
  • The role of primary cilia in thyroid diseases
    Zijiao Tian, Xinlin Li, Xue Yu, Shuxin Yan, Jingwei Sun, Wenxin Ma, Xiaoyun Zhu, Yang Tang
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Exome sequencing to explore the possibility of predicting genetic susceptibility to the joint occurrence of polycystic ovary syndrome and Hashimoto’s thyroiditis
    Natalia Zeber-Lubecka, Katarzyna Suchta, Maria Kulecka, Anna Kluska, Magdalena Piątkowska, Michal J. Dabrowski, Katarzyna Jankowska, Monika Grymowicz, Roman Smolarczyk, Ewa E. Hennig
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Molecular Mechanisms in Autoimmune Thyroid Disease
    Hernando Vargas-Uricoechea
    Cells.2023; 12(6): 918.     CrossRef
  • Identification of multiple novel susceptibility genes associated with autoimmune thyroid disease
    Xueying Liu, Yahu Miao, Chao Liu, Wan Lu, Qing Feng, Qiu Zhang
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Novel Susceptibility Genes Drive Familial Non-Medullary Thyroid Cancer in a Large Consanguineous Kindred
    Pierre Majdalani, Uri Yoel, Tayseer Nasasra, Merav Fraenkel, Alon Haim, Neta Loewenthal, Raz Zarivach, Eli Hershkovitz, Ruti Parvari
    International Journal of Molecular Sciences.2023; 24(9): 8233.     CrossRef
  • An Optimized Flow Cytometric Method to Demonstrate the Differentiation Stage-Dependent Ca2+ Flux Responses of Peripheral Human B Cells
    Anna Bajnok, Timea Serény-Litvai, Viktória Temesfői, Jasper Nörenberg, Róbert Herczeg, Ambrus Kaposi, Timea Berki, Emese Mezosi
    International Journal of Molecular Sciences.2023; 24(10): 9107.     CrossRef
  • FOXE1 Contributes to the Development of Psoriasis by Regulating WNT5A
    Meng Liu, Guanfei Zhang, Ziyang Wang, Xinyi Liu, Ke He, Ruiting Luo, Qiqi Duan, Ruimin Bai, Yuqian Wang, Wenqian Du, Yan Zheng, Yongping Shao
    Journal of Investigative Dermatology.2023; 143(12): 2366.     CrossRef
  • Correlation analysis of HHV-6A viral load and anti-TPO antibody levels in patients with Hashimoto's thyroiditis
    Noorossadat Seyyedi, Fariba Esfandiyari, Gholamreza Rafiei Dehbidi, Ali Farhadi, Farahnaz Zare, Sepide Namdari, Golrokh Bahmani, Banafsheh Rastegari, Farzaneh Zarghampoor, Abbas Behzad-Behbahani
    Future Virology.2023; 18(8): 527.     CrossRef
  • Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin
    Poupak Fallahi, Silvia Martina Ferrari, Giusy Elia, Francesca Ragusa, Armando Patrizio, Sabrina Rosaria Paparo, Gianni Marone, Maria Rosaria Galdiero, Giovanni Guglielmi, Rudy Foddis, Alfonso Cristaudo, Alessandro Antonelli
    Seminars in Cancer Biology.2022; 79: 203.     CrossRef
  • The Relationship between PTPN22 R620W Polymorphisms and the Susceptibility to Autoimmune Thyroid Diseases: An Updated Meta-analysis
    Huaiyong Wu, Siyuan Wan, Mengying Qu, Bingxuan Ren, Lixiang Liu, Hongmei Shen
    Immunological Investigations.2022; 51(2): 438.     CrossRef
  • Identification of Transcriptional Pattern Related to Immune Cell Infiltration With Gene Co-Expression Network in Papillary Thyroid Cancer
    Meiye Li, Jimei Zhang, Zongjing Zhang, Ying Qian, Wei Qu, Zhaoshun Jiang, Baochang Zhao
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Analysis of rare genetic variation underlying cardiometabolic diseases and traits among 200,000 individuals in the UK Biobank
    Sean J. Jurgens, Seung Hoan Choi, Valerie N. Morrill, Mark Chaffin, James P. Pirruccello, Jennifer L. Halford, Lu-Chen Weng, Victor Nauffal, Carolina Roselli, Amelia W. Hall, Matthew T. Oetjens, Braxton Lagerman, David P. vanMaanen, Goncalo Abecasis, Xiao
    Nature Genetics.2022; 54(3): 240.     CrossRef
  • Factors affecting recurrence in subacute granulomatous thyroiditis
    Çiğdem Tura Bahadir, Merve Yilmaz, Elif Kiliçkan
    Archives of Endocrinology and Metabolism.2022;[Epub]     CrossRef
  • Shared etiology of type 1 diabetes and Hashimoto’s thyroiditis: a population-based twin study
    Jakob Skov, Ralf Kuja-Halkola, Patrik K E Magnusson, Soffia Gudbjörnsdottir, Olle Kämpe, Sophie Bensing
    European Journal of Endocrinology.2022; 186(6): 677.     CrossRef
  • High Prevalence of Common Human Viruses in Thyroid Tissue
    Therese Weider, Angelo Genoni, Francesco Broccolo, Trond H. Paulsen, Knut Dahl-Jørgensen, Antonio Toniolo, Sara Salehi Hammerstad
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • B cells from anti-thyroid antibody positive, infertile women show hyper-reactivity to BCR stimulation
    Timea Serény-Litvai, Anna Bajnok, Viktoria Temesfoi, Jasper Nörenberg, Greta Pham-Dobor, Ambrus Kaposi, Akos Varnagy, Kalman Kovacs, Sandor Pentek, Tamas Koszegi, Emese Mezosi, Timea Berki
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • What do the structures of GCN5-containing complexes teach us about their function?
    Dominique Helmlinger, Gábor Papai, Didier Devys, László Tora
    Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms.2021; 1864(2): 194614.     CrossRef
  • Genetic Susceptibility to Joint Occurrence of Polycystic Ovary Syndrome and Hashimoto’s Thyroiditis: How Far Is Our Understanding?
    Natalia Zeber-Lubecka, Ewa E. Hennig
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • Type 1 Diabetes and Autoimmune Thyroid Disease—The Genetic Link
    Lara Frommer, George J. Kahaly
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Familial Risk of Hashimoto's Thyroiditis Among First-Degree Relatives: A Population-Based Study in Korea
    Hyun Jung Kim, Sayada Zartasha Kazmi, Taeuk Kang, Seo Young Sohn, Dong-Sook Kim, Hoo Jae Hann, Hyeong Sik Ahn
    Thyroid.2021; 31(7): 1096.     CrossRef
  • Limited Genetic Overlap Between Overt Hashimoto’s Thyroiditis and Graves’ Disease in Twins: A Population-based Study
    Jakob Skov, Jan Calissendorff, Daniel Eriksson, Patrik Magnusson, Olle Kämpe, Sophie Bensing, Ralf Kuja-Halkola
    The Journal of Clinical Endocrinology & Metabolism.2021; 106(4): e1101.     CrossRef
  • Endogenous and Synthetic Regulators of the Peripheral Components of the Hypothalamo-Hypophyseal-Gonadal and -Thyroid Axes
    A. O. Shpakov
    Neuroscience and Behavioral Physiology.2021; 51(3): 332.     CrossRef
  • Programmed Cell Death-Ligand 1 (PD-L1) gene Single Nucleotide Polymorphism in Graves’ Disease and Hashimoto’s Thyroiditis in Korean Patients
    Jee Hee Yoon, Min-ho Shin, Hee Nam Kim, Wonsuk Choi, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
    Endocrinology and Metabolism.2021; 36(3): 599.     CrossRef
  • Predisposition to Graves’ disease and Graves’ ophthalmopathy by genetic variants of IL2RA
    Juan Du, Xin Wang, Guiqin Tan, Wenwen Wei, Fangyu Zhou, Zhongzhi Liang, Hua Li, Hongsong Yu
    Journal of Molecular Medicine.2021; 99(10): 1487.     CrossRef
  • Association of IL-1β, NLRP3, and COX-2 Gene Polymorphisms with Autoimmune Thyroid Disease Risk and Clinical Features in the Iranian Population
    Zahra Heidari, Saeedeh Salimi, Mohsen Rokni, Mahnaz Rezaei, Neshat Khalafi, Mahdieh Jafari Shahroudi, Azizallah Dehghan, Mohsen Saravani, Rafael S. De Molon
    BioMed Research International.2021; 2021: 1.     CrossRef
  • Genetic polymorphisms in the PCNXL2 gene are risk factors for thyroid cancer in the Chinese population
    Runmei Hao, Peng Han, Ling Zhang, Ying Bi, Jinfeng Yan, Honghui Li, Yanxia Bai, Chongwen Xu, Baiya Li, Huajing Li
    Future Oncology.2021; 17(34): 4677.     CrossRef
  • Genetic Variants Associated with Thyroid Cancer Risk: Comprehensive Research Synopsis, Meta-Analysis, and Cumulative Epidemiological Evidence
    Ran Ran, Gang Tu, Hui Li, Hao Wang, Exian Mou, Caiyang Liu, Yuan Seng Wu
    Journal of Oncology.2021; 2021: 1.     CrossRef
  • The Identification of Three Key Genes Related to Stemness in Thyroid Carcinoma through Comprehensive Analysis
    Tonglong Zhang, Chunhong Yan, Zhengdu Ye, Xingling Yin, Tian-an Jiang
    Combinatorial Chemistry & High Throughput Screening.2021; 24(3): 423.     CrossRef
  • Епідеміологія автоімунного тиреоїдиту
    V.I. Кravchenko, О.А. Тоvkay, О.V. Rakov, М.D. Тronko
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2021; 17(2): 136.     CrossRef
  • Thyroid autoimmune disorders and cancer
    Silvia Martina Ferrari, Poupak Fallahi, Giusy Elia, Francesca Ragusa, Ilaria Ruffilli, Sabrina Rosaria Paparo, Alessandro Antonelli
    Seminars in Cancer Biology.2020; 64: 135.     CrossRef
  • Association of FCRL3 rs7528684 polymorphism with risk of Hashimoto's thyroiditis in Iranian patients
    Kurosh Kalantar, Farzad Ghandehari, Saeed Malek-Hosseini, Hossein Golmoghaddam, Davood Rostamzadeh, Mohamad Hossein Dabbaghmanesh, Zahra Amirghofran
    Meta Gene.2020; 24: 100663.     CrossRef
  • Differentiated thyroid cancer and Hashimoto thyroiditis: Utility of the Afirma gene expression classifier
    Vardan Papoian, Jennifer E. Rosen, Wen Lee, Leonard Wartofsky, Erin A. Felger
    Journal of Surgical Oncology.2020; 121(7): 1053.     CrossRef
  • Familial risks between Graves disease and Hashimoto thyroiditis and other autoimmune diseases in the population of Sweden
    Hauke Thomsen, Xinjun Li, Kristina Sundquist, Jan Sundquist, Asta Försti, Kari Hemminki
    Journal of Translational Autoimmunity.2020; 3: 100058.     CrossRef
  • Association of rs944289, rs965513, and rs1443434 in TITF1/TITF2 with Risks of Papillary Thyroid Carcinoma and with Nodular Goiter in Northern Chinese Han Populations
    Xin Zhang, Yulu Gu, Yong Li, Heran Cui, Xiaoli Liu, Hui Sun, Qiong Yu, Yaqin Yu, Yawen Liu, Siyan Zhan, Yi Cheng
    International Journal of Endocrinology.2020; 2020: 1.     CrossRef
  • FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease
    Saedis Saevarsdottir, Thorunn A. Olafsdottir, Erna V. Ivarsdottir, Gisli H. Halldorsson, Kristbjorg Gunnarsdottir, Asgeir Sigurdsson, Ari Johannesson, Jon K. Sigurdsson, Thorhildur Juliusdottir, Sigrun H. Lund, Asgeir O. Arnthorsson, Edda L. Styrmisdottir
    Nature.2020; 584(7822): 619.     CrossRef
  • Genetic relationship between Hashimoto`s thyroiditis and papillary thyroid carcinoma with coexisting Hashimoto`s thyroiditis
    Ohoud Subhi, Hans-Juergen Schulten, Nadia Bagatian, Roa'a Al-Dayini, Sajjad Karim, Sherin Bakhashab, Reem Alotibi, Alaa Al-Ahmadi, Manar Ata, Aisha Elaimi, Saad Al-Muhayawi, Majid Mansouri, Khalid Al-Ghamdi, Osman Abdel Hamour, Awatif Jamal, Jaudah Al-Mag
    PLOS ONE.2020; 15(6): e0234566.     CrossRef
  • Thyroid cancer and thyroid autoimmune disease: A review of molecular aspects and clinical outcomes
    Natália Medeiros Dias Lopes, Hannah Hamada Mendonça Lens, André Armani, Poliana Camila Marinello, Alessandra Lourenço Cecchini
    Pathology - Research and Practice.2020; 216(9): 153098.     CrossRef
  • Immune gene signature delineates a subclass of thyroid cancer with unfavorable clinical outcomes
    Jingtai Zhi, Jiaoyu Yi, Mengran Tian, Huijuan Wang, Ning Kang, Xiangqian Zheng, Ming Gao
    Aging.2020; 12(7): 5733.     CrossRef
  • VARIETY OF COMBINATIONS OF HASHIMOTO’S THYROIDITIS WITH OTHER BACKGROUND PATHOLOGY OF THYROID PARENCHEMA IN DIFFERENT FORMS OF THYROID CANCER
    Yu. I. Karachentsev, V. M. Dubovik, I. V. Gopkalova, V. V. Khaziev, S. S. Sokolova, Y. P. Korchagin, N. G. Filonenko, M. Y. Sazonov, L. V. Gerasimenko
    Bulletin of Problems Biology and Medicine.2020; 3(1): 105.     CrossRef
  • Analysis of Polymorphisms rs7093069-IL-2RA, rs7138803-FAIM2, and rs1748033-PADI4 in the Group of Adolescents With Autoimmune Thyroid Diseases
    Beata Sawicka, Hanna Borysewicz-Sańczyk, Natalia Wawrusiewicz-Kurylonek, Tommaso Aversa, Domenico Corica, Joanna Gościk, Adam Krętowski, Małgorzata Waśniewska, Artur Bossowski
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • Familial associations for rheumatoid autoimmune diseases
    Hauke Thomsen, Xinjun Li, Kristina Sundquist, Jan Sundquist, Asta Försti, Kari Hemminki
    Rheumatology Advances in Practice.2020;[Epub]     CrossRef
  • Familial risks between giant cell arteritis and Takayasu arteritis and other autoimmune diseases in the population of Sweden
    Hauke Thomsen, Xinjun Li, Kristina Sundquist, Jan Sundquist, Asta Försti, Kari Hemminki
    Scientific Reports.2020;[Epub]     CrossRef
  • The Association of Obesity with Autoimmune Thyroiditis and Thyroid Function-Possible Mechanisms of Bilateral Interaction
    Agnieszka Baranowska-Bik, Wojciech Bik, Henrik Falhammar
    International Journal of Endocrinology.2020; 2020: 1.     CrossRef
  • The Risk of Recurrence of Subacute Thyroiditis Is HLA-Dependent
    Magdalena Stasiak, Bogusław Tymoniuk, Bartłomiej Stasiak, Andrzej Lewiński
    International Journal of Molecular Sciences.2019; 20(5): 1089.     CrossRef
  • FOXE1 inhibits cell proliferation, migration and invasion of papillary thyroid cancer by regulating PDGFA
    Zheng Ding, Ronghu Ke, Yong Zhang, Youben Fan, Jianxia Fan
    Molecular and Cellular Endocrinology.2019; 493: 110420.     CrossRef
  • Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer
    Kinga Hińcza, Artur Kowalik, Aldona Kowalska
    Genes.2019; 10(7): 482.     CrossRef
  • Thyroid Cancer: The Quest for Genetic Susceptibility Involving DNA Repair Genes
    Santos, Gomes, Bastos, Gil, Azevedo, Ferreira, Limbert, Silva, Rueff
    Genes.2019; 10(8): 586.     CrossRef
  • Genetic Polymorphisms on 4q21.1 Contributed to the Risk of Hashimoto's Thyroiditis
    Dachao Mo, Junjiu Li, Liang Peng, Zhiyuan Liu, Jieyun Wang, Jiru Yuan
    Genetic Testing and Molecular Biomarkers.2019; 23(12): 837.     CrossRef
  • A Weighted Genetic Risk Score Using Known Susceptibility Variants to Predict Graves Disease Risk
    Yu-Ru Ma, Shuang-Xia Zhao, Lu Li, Feng Sun, Xiao-Ping Ye, Fei-Fei Yuan, Dan Jiang, Zheng Zhou, Qian-Yue Zhang, Yue-Yue Wan, Guang-Ya Zhang, Jing Wu, Rui-Jia Zhang, Ya Fang, Huai-Dong Song
    The Journal of Clinical Endocrinology & Metabolism.2019; 104(6): 2121.     CrossRef
  • Architects meets Repairers: The interplay between homeobox genes and DNA repair
    Bruno César Feltes
    DNA Repair.2019; 73: 34.     CrossRef
  • Development of a prognostic index based on an immunogenomic landscape analysis of papillary thyroid cancer
    Peng Lin, Yi-nan Guo, Lin Shi, Xiao-jiao Li, Hong Yang, Yun He, Qing Li, Yi-wu Dang, Kang-lai Wei, Gang Chen
    Aging.2019; 11(2): 480.     CrossRef
  • Selenium and Selenoproteins in Immune Mediated Thyroid Disorders
    Liliana Santos, Celestino Neves, Miguel Melo, Paula Soares
    Diagnostics.2018; 8(4): 70.     CrossRef
  • Sex-specific genetic influence on thyroid-stimulating hormone and free thyroxine levels, and interactions between measurements: KNHANES 2013–2015
    Young Ki Lee, Dong Yeob Shin, Hyejung Shin, Eun Jig Lee, Silvia Naitza
    PLOS ONE.2018; 13(11): e0207446.     CrossRef
Close layer
Thyroid
Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro)
Jae Hoon Moon, Ji-hoon Kim, Eun Kyung Lee, Kyu Eun Lee, Sung Hye Kong, Yeo Koon Kim, Woo-jin Jung, Chang Yoon Lee, Roh-Eul Yoo, Yul Hwangbo, Young Shin Song, Min Joo Kim, Sun Wook Cho, Su-jin Kim, Eun Jae Jung, June Young Choi, Chang Hwan Ryu, You Jin Lee, Jeong Hun Hah, Yuh-Seog Jung, Junsun Ryu, Yunji Hwang, Sue K. Park, Ho Kyung Sung, Ka Hee Yi, Do Joon Park, Young Joo Park
Endocrinol Metab. 2018;33(2):278-286.   Published online June 21, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.2.278
  • 5,174 View
  • 88 Download
  • 30 Web of Science
  • 31 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

The ongoing Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro) aims to observe the natural course of papillary thyroid microcarcinoma (PTMC), develop a protocol for active surveillance (AS), and compare the long-term prognosis, quality of life, and medical costs between the AS and immediate surgery groups.

Methods

This multicenter prospective cohort study of PTMC started in June 2016. The inclusion criteria were suspicious of malignancy or malignancy based on fine needle aspiration or core needle biopsy, age of ≥18 years, and a maximum diameter of ≤1 cm. If there was no major organ involvement, no lymph node/distant metastasis, and no variants with poor prognosis, the patients were explained of the pros and cons of immediate surgery and AS before selecting AS or immediate surgery. Follow-up visits (physical examination, ultrasonography, thyroid function, and questionnaires) are scheduled every 6 months during the first 2 years, and then every 1 year thereafter. Progression was defined as a maximum diameter increase of ≥3, ≥2 mm in two dimensions, suspected organ involvement, or lymph node/distant metastasis.

Results

Among 439 enrolled patients, 290 patients (66.1%) chose AS and 149 patients (33.9%) chose immediate surgery. The median follow-up was 6.7 months (range, 0.2 to 11.9). The immediate surgery group had a larger maximum tumor diameter, compared to the AS group (7.1±1.9 mm vs. 6.6±2.0 mm, respectively; P=0.014).

Conclusion

The results will be useful for developing an appropriate PTMC treatment policy based on its natural course and risk factors for progression.

Citations

Citations to this article as recorded by  
  • Psychological adjustment to initial treatment for low‐risk thyroid cancer: Preliminary study
    Gabriella T. Seo, Mark L. Urken, Lauren E. Wein, Michael P. Saturno, Danielle Kapustin, Monica H. Xing, Lauren E. Yue, Eric M. Dowling, Tracey A. Revenson, Katherine J. Roberts, Robert Michael Tuttle
    Head & Neck.2023; 45(2): 439.     CrossRef
  • Response to Letter to the Editor on Surgical Outcomes in Patients With Low-Risk Papillary Thyroid Microcarcinoma From MAeSTro Study: Immediate Operation Versus Delayed Operation Following Active Surveillance: A Multicenter Prospective Cohort Study
    Hyeonuk Hwang, June Young Choi, Jae Hoon Moon, Eun Kyung Lee, Young Joo Park, Su-jin Kim, Yuh-Seog Jung
    Annals of Surgery Open.2023; 4(3): e311.     CrossRef
  • Lower Thyroid Cancer Mortality in Patients Detected by Screening: A Meta-Analysis
    Shinje Moon, Young Shin Song, Kyong Yeun Jung, Eun Kyung Lee, Young Joo Park
    Endocrinology and Metabolism.2023; 38(1): 93.     CrossRef
  • To Screen or Not to Screen?
    Do Joon Park
    Endocrinology and Metabolism.2023; 38(1): 69.     CrossRef
  • Surgical Outcomes in Patients With Low-risk Papillary Thyroid Microcarcinoma From MAeSTro Study
    Hyeonuk Hwang, June Young Choi, Hyeong Won Yu, Jae Hoon Moon, Ji-hoon Kim, Eun Kyung Lee, Yeo Koon Kim, Chang Yoon Lee, Sun Wook Cho, Eun-Jae Chung, Chang Hwan Ryu, Junsun Ryu, Ka Hee Yi, Do Joon Park, Kyu Eun Lee, Young Joo Park, Su-jin Kim, Yuh-Seog Jun
    Annals of Surgery.2023; 278(5): e1087.     CrossRef
  • US Predictors of Papillary Thyroid Microcarcinoma Progression at Active Surveillance
    Ji Ye Lee, Ji-hoon Kim, Yeo Koon Kim, Chang Yoon Lee, Eun Kyung Lee, Jae Hoon Moon, Hoon Sung Choi, Hwangbo Yul, Sun Wook Cho, Su-jin Kim, Kyu Eun Lee, Do Joon Park, Young Joo Park
    Radiology.2023;[Epub]     CrossRef
  • MET-receptor targeted fluorescent imaging and spectroscopy to detect multifocal papillary thyroid cancer
    Madelon J. H. Metman, Pascal K. C. Jonker, Luc H. J. Sondorp, Bettien M. van Hemel, Mark S. Sywak, Anthony J. Gill, Liesbeth Jansen, Paul J. van Diest, Tessa M. van Ginhoven, Clemens W. G. M. Löwik, Anh H. Nguyen, Dominic J. Robinson, Gooitzen M. van Dam,
    European Journal of Nuclear Medicine and Molecular Imaging.2023;[Epub]     CrossRef
  • Active Surveillance of Thyroid Microcarcinomas: a Critical View
    Claudio R. Cernea, Leandro Luongo Matos, Cecília Eugênio, Giovanna Mattos Ferreira, Yasmin Sa Cerqueira, Ana Kober N. Leite, Felipe A. B. Vanderlei, Dorival de Carlucci, Renato N. Gotoda, Flávio C. Hojaij, Vergilius J. F. Araújo-Filho
    Current Oncology Reports.2022; 24(1): 69.     CrossRef
  • Active Surveillance Versus Thyroid Surgery for Differentiated Thyroid Cancer: A Systematic Review
    Roger Chou, Tracy Dana, Megan Haymart, Angela M. Leung, Ralph P. Tufano, Julie Ann Sosa, Matthew D. Ringel
    Thyroid.2022; 32(4): 351.     CrossRef
  • A Review of Active Surveillance of Papillary Thyroid Microcarcinoma
    Cho Rok Lee
    Journal of Endocrine Surgery.2022; 22(1): 1.     CrossRef
  • Active Surveillance Versus Immediate Surgery for Low-Risk Papillary Thyroid Microcarcinoma Patients in South Korea: A Cost-Minimization Analysis from the MAeSTro Study
    Kyungsik Kim, June Young Choi, Su-jin Kim, Eun Kyung Lee, Young Ki Lee, Jun Sun Ryu, Kyu Eun Lee, Jae Hoon Moon, Young Joo Park, Sun Wook Cho, Sue K. Park
    Thyroid.2022; 32(6): 648.     CrossRef
  • A cross-sectional survey of patient treatment choice in a multicenter prospective cohort study on active surveillance of papillary thyroid microcarcinoma (MAeSTro)
    Yul Hwangbo, June Young Choi, Eun Kyung Lee, Chang Hwan Ryu, Sun Wook Cho, Eun Jae Chung, Jeong Hun Hah, Woo-Jin Jeong, Sue K. Park, Yuh-Seog Jung, Ji-hoon Kim, Min Joo Kim, Su-jin Kim, Yeo Koon Kim, Chang Yoon Lee, Ji Ye Lee, You Jin Lee, Hyeong Won Yu,
    Thyroid.2022;[Epub]     CrossRef
  • Progression of Low-Risk Papillary Thyroid Microcarcinoma During Active Surveillance: Interim Analysis of a Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma in Korea
    Eun Kyung Lee, Jae Hoon Moon, Yul Hwangbo, Chang Hwan Ryu, Sun Wook Cho, June Young Choi, Eun-Jae Chung, Woo-Jin Jeong, Yuh-Seog Jung, Junsun Ryu, Su-jin Kim, Min Joo Kim, Yeo Koon Kim, Chang Yoon Lee, Ji Ye Lee, Hyeong Won Yu, Jeong Hun Hah, Kyu Eun Lee,
    Thyroid.2022; 32(11): 1328.     CrossRef
  • Indications and Strategy for Active Surveillance of Adult Low-Risk Papillary Thyroid Microcarcinoma: Consensus Statements from the Japan Association of Endocrine Surgery Task Force on Management for Papillary Thyroid Microcarcinoma
    Iwao Sugitani, Yasuhiro Ito, Dai Takeuchi, Hirotaka Nakayama, Chie Masaki, Hisakazu Shindo, Masanori Teshima, Kazuhiko Horiguchi, Yusaku Yoshida, Toshiharu Kanai, Mitsuyoshi Hirokawa, Kiyomi Y. Hames, Isao Tabei, Akira Miyauchi
    Thyroid.2021; 31(2): 183.     CrossRef
  • Effect of Initial Treatment Choice on 2-year Quality of Life in Patients with Low-risk Papillary Thyroid Microcarcinoma
    Jae Hoon Moon, Chang Hwan Ryu, Sun Wook Cho, June Young Choi, Eun-Jae Chung, Jeong Hun Hah, Yul Hwangbo, Woo-Jin Jeong, Yuh-Seog Jung, Ji-hoon Kim, Min Joo Kim, Su-jin Kim, Yeo Koon Kim, Chang Yoon Lee, Eun Kyung Lee, Ji Ye Lee, Kyu Eun Lee, You Jin Lee,
    The Journal of Clinical Endocrinology & Metabolism.2021; 106(3): 724.     CrossRef
  • Adoption of Active Surveillance for Very Low-Risk Differentiated Thyroid Cancer in the United States: A National Survey
    Susan C Pitt, Nan Yang, Megan C Saucke, Nicholas Marka, Bret Hanlon, Kristin L Long, Alexandria D McDow, J P Brito, Benjamin R Roman
    The Journal of Clinical Endocrinology & Metabolism.2021; 106(4): 1728.     CrossRef
  • Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma
    Min Ji Jeon, Yea Eun Kang, Jae Hoon Moon, Dong Jun Lim, Chang Yoon Lee, Yong Sang Lee, Sun Wook Kim, Min-Hee Kim, Bo Hyun Kim, Ho-Cheol Kang, Minho Shong, Sun Wook Cho, Won Bae Kim
    Endocrinology and Metabolism.2021; 36(2): 359.     CrossRef
  • Multifocality and Progression of Papillary Thyroid Microcarcinoma During Active Surveillance
    Ryuta Nagaoka, Aya Ebina, Kazuhisa Toda, Tomoo Jikuzono, Marie Saitou, Masaomi Sen, Hiroko Kazusaka, Mami Matsui, Keiko Yamada, Hiroki Mitani, Iwao Sugitani
    World Journal of Surgery.2021; 45(9): 2769.     CrossRef
  • Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma
    Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Endocrinology and Metabolism.2021; 36(4): 717.     CrossRef
  • The Concept of Economic Evaluation and Its Application in Thyroid Cancer Research
    Kyungsik Kim, Mijin Kim, Woojin Lim, Bo Hyun Kim, Sue K. Park
    Endocrinology and Metabolism.2021; 36(4): 725.     CrossRef
  • Genomic and Transcriptomic Characteristics According to Size of Papillary Thyroid Microcarcinoma
    Young Shin Song, Byung-Hee Kang, Seungbok Lee, Seong-Keun Yoo, Young Sik Choi, Jungsun Park, Dong Yoon Park, Kyu Eun Lee, Jeong-Sun Seo, Young Joo Park
    Cancers.2020; 12(5): 1345.     CrossRef
  • Experience with Active Surveillance of Thyroid Low-Risk Carcinoma in a Developing Country
    Alvaro Sanabria
    Thyroid.2020; 30(7): 985.     CrossRef
  • Association of Patient Age With Progression of Low-risk Papillary Thyroid Carcinoma Under Active Surveillance
    Alexandra Koshkina, Rouhi Fazelzad, Iwao Sugitani, Akira Miyauchi, Lehana Thabane, David P. Goldstein, Sangeet Ghai, Anna M. Sawka
    JAMA Otolaryngology–Head & Neck Surgery.2020; 146(6): 552.     CrossRef
  • Active surveillance in low risk papillary thyroid carcinoma
    Fabian Pitoia, Anabella Smulever
    World Journal of Clinical Oncology.2020; 11(6): 320.     CrossRef
  • Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival
    Jolanta Krajewska, Aleksandra Kukulska, Malgorzata Oczko-Wojciechowska, Agnieszka Kotecka-Blicharz, Katarzyna Drosik-Rutowicz, Malgorzata Haras-Gil, Barbara Jarzab, Daria Handkiewicz-Junak
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • The dilemma of papillary thyroid microcarcinoma management. To operate or not to operate, that is the question
    Juan C Galofré
    Endocrinología, Diabetes y Nutrición.2019; 66(8): 469.     CrossRef
  • Computed Tomography for Detecting Cervical Lymph Node Metastasis in Patients Who Have Papillary Thyroid Microcarcinoma with Tumor Characteristics Appropriate for Active Surveillance
    Dong-Hwa Lee, Yeo Koon Kim, Hyeong Won Yu, June Young Choi, So Yeon Park, Jae Hoon Moon
    Thyroid.2019; 29(11): 1653.     CrossRef
  • The dilemma of papillary thyroid microcarcinoma management. To operate or not to operate, that is the question
    Juan C Galofré
    Endocrinología, Diabetes y Nutrición (English ed.).2019; 66(8): 469.     CrossRef
  • Longitudinal Assessment of Quality of Life According to Treatment Options in Low-Risk Papillary Thyroid Microcarcinoma Patients: Active Surveillance or Immediate Surgery (Interim Analysis of MAeSTro)
    Sung Hye Kong, Junsun Ryu, Min Joo Kim, Sun Wook Cho, Young Shin Song, Ka Hee Yi, Do Joon Park, Yul Hwangbo, You Jin Lee, Kyu Eun Lee, Su-jin Kim, Woo-Jin Jeong, Eun-Jae Chung, Jeong Hun Hah, June Young Choi, Chang Hwan Ryu, Yuh-Seog Jung, Jae Hoon Moon,
    Thyroid.2019; 29(8): 1089.     CrossRef
  • Ultrasound-guided percutaneous laser ablation for papillary thyroid microcarcinoma: a retrospective analysis of 37 patients
    Lili Ji, Qin Wu, Jun Gu, Xuedong Deng, Wei Zhou, Xing Fan, Feng Zhou
    Cancer Imaging.2019;[Epub]     CrossRef
  • Evolving management considerations in active surveillance for micropapillary thyroid carcinoma
    Allen S. Ho, Irene Chen, Michelle Melany, Wendy L. Sacks
    Current Opinion in Endocrinology, Diabetes & Obesity.2018; 25(5): 353.     CrossRef
Close layer
Acute Hyperglycemia Associated with Anti-Cancer Medication
Yul Hwangbo, Eun Kyung Lee
Endocrinol Metab. 2017;32(1):23-29.   Published online March 20, 2017
DOI: https://doi.org/10.3803/EnM.2017.32.1.23
  • 5,956 View
  • 124 Download
  • 41 Web of Science
  • 43 Crossref
AbstractAbstract PDFPubReader   

Hyperglycemia during chemotherapy occurs in approximately 10% to 30% of patients. Glucocorticoids and L-asparaginase are well known to cause acute hyperglycemia during chemotherapy. Long-term hyperglycemia is also frequently observed, especially in patients with hematologic malignancies treated with L-asparaginase-based regimens and total body irradiation. Glucocorticoid-induced hyperglycemia often develops because of increased insulin resistance, diminished insulin secretion, and exaggerated hepatic glucose output. Screening strategies for this condition include random glucose testing, hemoglobin A1c testing, oral glucose loading, and fasting plasma glucose screens. The management of hyperglycemia starts with insulin or sulfonylurea, depending on the type, dose, and delivery of the glucocorticoid formulation. Mammalian target of rapamycin (mTOR) inhibitors are associated with a high incidence of hyperglycemia, ranging from 13% to 50%. Immunotherapy, such as anti-programmed death 1 (PD-1) antibody treatment, induces hyperglycemia with a prevalence of 0.1%. The proposed mechanism of immunotherapy-induced hyperglycemia is an autoimmune process (insulitis). Withdrawal of the PD-1 inhibitor is the primary treatment for severe hyperglycemia. The efficacy of glucocorticoid therapy is not fully established and the decision to resume PD-1 inhibitor therapy depends on the severity of the hyperglycemia. Diabetic patients should achieve optimized glycemic control before initiating treatment, and glucose levels should be monitored periodically in patients initiating mTOR inhibitor or PD-1 inhibitor therapy. With regard to hyperglycemia caused by anti-cancer therapy, frequent monitoring and proper management are important for promoting the efficacy of anti-cancer therapy and improving patients' quality of life.

Citations

Citations to this article as recorded by  
  • Bridging the Gap: Pancreas Tissue Slices From Organ and Tissue Donors for the Study of Diabetes Pathogenesis
    Christian M. Cohrs, Chunguang Chen, Mark A. Atkinson, Denise M. Drotar, Stephan Speier
    Diabetes.2024; 73(1): 11.     CrossRef
  • Assessment of metabolic syndrome parameters in pediatric acute lymphoblastic leukemia survivors
    Ömer Kartal, Orhan Gürsel
    Indian Journal of Cancer.2023; 60(3): 325.     CrossRef
  • Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database
    Minyoung Lee, Kyeongseob Jeong, Yu Rang Park, Yumie Rhee
    Metabolism.2023; 138: 155311.     CrossRef
  • Analysis of the Incidence of Type 2 Diabetes, Requirement of Insulin Treatment, and Diabetes-Related Complications among Patients with Cancer
    Su Jung Lee, Chulho Kim, Hyunjae Yu, Dong-Kyu Kim
    Cancers.2023; 15(4): 1094.     CrossRef
  • A Case of Pembrolizumab-Induced Diabetic Ketoacidosis and Hyperthyroidism in a Patient With Recurrent Esophageal Adenocarcinoma
    Jonathan Salangsang, Surendra Sapkota, Sanjeev Kharel, Prakash Gupta, Abhishek Kalla
    Cureus.2023;[Epub]     CrossRef
  • Link between Blood Cell-Associated Inflammatory Indices and Chemotherapy-Induced Hyperglycemia in Women Affected with Breast Cancer: Clinical Studies
    Krishna Prasad, Suresh Rao, Sanath Kumar Hegde, Thomas George, Rhea Katherine D'souza, Sucharitha Suresh, Manjeshwar Shrinath Baliga
    South Asian Journal of Cancer.2023; 12(02): 118.     CrossRef
  • Insulin resistance in patients with cancer: a systematic review and meta-analysis
    Joan M. Màrmol, Michala Carlsson, Steffen H. Raun, Mia K. Grand, Jonas Sørensen, Louise Lang Lehrskov, Erik A. Richter, Ole Norgaard, Lykke Sylow
    Acta Oncologica.2023; 62(4): 364.     CrossRef
  • Metabolic obesity phenotypes and obesity‐related cancer risk in the National Health and Nutrition Examination Survey
    Maci Winn, Prasoona Karra, Heinz Freisling, Marc J. Gunter, Benjamin Haaland, Michelle L. Litchman, Jennifer A. Doherty, Mary C. Playdon, Sheetal Hardikar
    Endocrinology, Diabetes & Metabolism.2023;[Epub]     CrossRef
  • Effects of Vitamin Intake on Blood Glucose in Cancer Patients Undergoing Chemotherapy: Quantitative and Descriptive Research
    Ji Yeong Kim, Kyung Hee Lim
    Korean Journal of Adult Nursing.2023; 35(2): 148.     CrossRef
  • Oncologists’ responsibility, comfort, and knowledge managing hyperglycemia in patients with cancer undergoing chemotherapy: a cross sectional study
    Teresa M. Salgado, Rotana M. Radwan, Erin Hickey Zacholski, Emily Mackler, Tonya M. Buffington, Kerri T. Musselman, William J. Irvin, Jennifer M. Perkins, Trang N. Le, Dave L. Dixon, Karen B. Farris, Vanessa B. Sheppard, Resa M. Jones
    Supportive Care in Cancer.2023;[Epub]     CrossRef
  • Diabetes management in cancer patients. An Italian Association of Medical Oncology, Italian Association of Medical Diabetologists, Italian Society of Diabetology, Italian Society of Endocrinology and Italian Society of Pharmacology multidisciplinary conse
    N. Silvestris, T. Franchina, M. Gallo, A. Argentiero, A. Avogaro, G. Cirino, A. Colao, R. Danesi, G. Di Cianni, S. D’Oronzo, A. Faggiano, S. Fogli, D. Giuffrida, S. Gori, N. Marrano, R. Mazzilli, M. Monami, M. Montagnani, L. Morviducci, A. Natalicchio, A.
    ESMO Open.2023; 8(6): 102062.     CrossRef
  • Prognostic Factors for Hyperglycemia in Patients Receiving Chemotherapy
    Jiyeong Kim, Kyung Hee Lim
    Cancer Nursing.2023;[Epub]     CrossRef
  • Severe Insulin Resistance in a Patient Treated With Nivolumab and Brentuximab-Vedotin for Hodgkin Lymphoma
    Elif Tama, Meghan Black, Muhamad Alhaj Moustafa, Maria D Hurtado
    JCEM Case Reports.2023;[Epub]     CrossRef
  • A New Hypothesis Describing the Pathogenesis of Oral Mucosal Injury Associated with the Mammalian Target of Rapamycin (mTOR) Inhibitors
    Stephen T. Sonis, Alessandro Villa
    Cancers.2023; 16(1): 68.     CrossRef
  • Management of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia
    Marcus D. Goncalves, Azeez Farooki
    Integrative Cancer Therapies.2022; 21: 153473542110731.     CrossRef
  • Metformin Induced Cognitive Impairment and Neuroinflammation in CMF-Treated Rats
    Ahmad H. Alhowai, Yasser Almogbel, Ahmed A.H. Abdel, Maha A. Aldubay, Hani A. Alfheeaid, Shatha G. Felemban, Sridevi Chigurupat, Ibrahim F. Alharbi, Hindi S. Alharbi
    International Journal of Pharmacology.2022; 18(2): 228.     CrossRef
  • Glucose Influences the Response of Glioblastoma Cells to Temozolomide and Dexamethasone
    Anna M Bielecka-Wajdman, Tomasz Ludyga, Daria Smyk, Wojciech Smyk, Magdalena Mularska, Patrycja Świderek, Wojciech Majewski, Christina Susanne Mullins, Michael Linnebacher, Ewa Obuchowicz
    Cancer Control.2022; 29: 107327482210754.     CrossRef
  • Cardiometabolic Comorbidities in Cancer Survivors
    Leah L. Zullig, Anthony D. Sung, Michel G. Khouri, Shelley Jazowski, Nishant P. Shah, Andrea Sitlinger, Dan V. Blalock, Colette Whitney, Robin Kikuchi, Hayden B. Bosworth, Matthew J. Crowley, Karen M. Goldstein, Igor Klem, Kevin C. Oeffinger, Susan Dent
    JACC: CardioOncology.2022; 4(2): 149.     CrossRef
  • Glucose deprivation reduces proliferation and motility, and enhances the anti-proliferative effects of paclitaxel and doxorubicin in breast cell lines in vitro
    Maitham A. Khajah, Sarah Khushaish, Yunus A. Luqmani, Yi-Hsien Hsieh
    PLOS ONE.2022; 17(8): e0272449.     CrossRef
  • Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression
    Kyeong-Min Lee, Yeo Jin Hwang, Gwon-Soo Jung
    Biochemical and Biophysical Research Communications.2022; 626: 135.     CrossRef
  • Glucocorticoid-Induced Hyperglycemia in Oncologic Outpatients: A Narrative Review Using the Quadruple Aim Framework
    Ihab Kandil, Erin Keely
    Canadian Journal of Diabetes.2022; 46(7): 730.     CrossRef
  • Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors
    Atika AlHarbi, Majed Alshamrani, Mansoor Khan, Abdelmajid Alnatsheh, Mohammed Aseeri
    Medical Sciences.2022; 10(4): 65.     CrossRef
  • The Assessment of the Hypothalamic-Pituitary-Adrenal Axis After Oncological Treatment in Pediatric Patients with Acute Lymphoblastic Leukemia
    Barbara Hull, Anna Wedrychowicz, Magdalena Ossowska, Aleksandra Furtak, Joanna Badacz, Szymon Skoczeń, Jerzy B. Starzyk
    Journal of Clinical Research in Pediatric Endocrinology.2022; 14(4): 393.     CrossRef
  • Targeting Mitochondria and Oxidative Stress in Cancer- and Chemotherapy-Induced Muscle Wasting
    Joshua R. Huot, Dryden Baumfalk, Aridai Resendiz, Andrea Bonetto, Ashley J. Smuder, Fabio Penna
    Antioxidants & Redox Signaling.2022;[Epub]     CrossRef
  • Onkodiabetológia III.
    Róbert János Bánhegyi, Blanka Veréb, Andrea Gazdag, Beatrix Rácz, Róbert Wagner, Norbert Fülöp, Béla Pikó
    Orvosi Hetilap.2022; 163(41): 1614.     CrossRef
  • Economic burden of diabetes among medicare beneficiaries with cancer
    Cassidi C McDaniel, F Ellen Loh, Devan M Rockwell, Courtney P McDonald, Chiahung Chou
    Journal of Pharmaceutical Health Services Research.2021; 12(2): 142.     CrossRef
  • The prognostic outcome of ‘type 2 diabetes mellitus and breast cancer’ association pivots on hypoxia-hyperglycemia axis
    Ilhaam Ayaz Durrani, Attya Bhatti, Peter John
    Cancer Cell International.2021;[Epub]     CrossRef
  • Increased risk of diabetes in cancer survivors: a pooled analysis of 13 population-based cohort studies
    Y. Xiao, H. Wang, Y. Tang, J. Yan, L. Cao, Z. Chen, Z. Shao, Z. Mei, Z. Jiang
    ESMO Open.2021; 6(4): 100218.     CrossRef
  • Sublethal concentrations of high glucose prolong mitotic arrest in a spindle assembly checkpoint activity dependent manner in budding yeast
    Pinar B. Thomas, Elif E. Cavusoglu, Nur Kaluc
    Biologia.2021; 76(12): 3883.     CrossRef
  • Hyperglycemia in Childhood Acute Lymphoblastic Leukemia During Induction Chemotherapy
    Nengcy Erlina Tasik Rerung, Andi Cahyadi, Nur Rochmah, Maria Christina Shanty Larasati, Mia Ratwita Andarsini, Muhammad Faizi, IDG Ugrasena, Bambang Permono
    MEDICINUS.2021; 34(1): 18.     CrossRef
  • Effect of Acute Chemotherapy on Glucose Levels in Rats
    Ahmad H. Alhowail, Gena S. Alfawzan, Maha A. Aldubayan, Lolwah S. Alsalam
    International Journal of Pharmacology.2020; 16(3): 276.     CrossRef
  • Predictors of Disease Progression or Performance Status Decline in Patients Undergoing Neoadjuvant Therapy for Localized Pancreatic Head Adenocarcinoma
    Alessandro Paniccia, Ana L. Gleisner, Mazen S. Zenati, Amr I. Al Abbas, Jae Pil Jung, Nathan Bahary, Kenneth K. W. Lee, David Bartlett, Melissa E. Hogg, Herbert J. Zeh, Amer H. Zureikat
    Annals of Surgical Oncology.2020; 27(8): 2961.     CrossRef
  • Fasting to enhance Cancer treatment in models: the next steps
    Jing Zhang, Yanlin Deng, Bee Luan Khoo
    Journal of Biomedical Science.2020;[Epub]     CrossRef
  • Concurrent diabetic ketoacidosis and pancreatitis in Paediatric acute lymphoblastic leukemia receiving L-asparaginase
    Patel Zeeshan Jameel, Sham Lohiya, Amol Dongre, Sachin Damke, Bhavana B. Lakhkar
    BMC Pediatrics.2020;[Epub]     CrossRef
  • Hyperglycemia during Adjuvant Chemotherapy as a Prognostic Factor in Breast Cancer Patients without Diabetes
    Ha Rim Ahn, Sang Yull Kang, Hyun Jo Youn, Sung Hoo Jung
    Journal of Breast Cancer.2020; 23(4): 398.     CrossRef
  • Side effects of adjuvant chemotherapy and their impact on outcome in elderly breast cancer patients: a cohort study
    Valentina Zanuso, Vittorio Fregoni, Lorenzo Gervaso
    Future Science OA.2020; : FSO617.     CrossRef
  • Incidence of Hyperglycemia/Secondary Diabetes in Women who have Undergone Curative Chemotherapy for Breast Cancer: First Study from India
    Suresh Rao, Krishna Prasad, Soniya Abraham, Thomas George, Supreeth Kakkaje Chandran, Manjeshwar Shrinath Baliga
    South Asian Journal of Cancer.2020; 09(03): 130.     CrossRef
  • Hyperglycemic ADR Distribution of Doxorubicin From VigiBase
    Jincheng Yang, Jun Yang
    American Journal of Therapeutics.2019; 26(3): e428.     CrossRef
  • Hyperglycemia During Childhood Cancer Therapy: Incidence, Implications, and Impact on Outcomes
    Allison Grimes, Ashraf Mohamed, Jenna Sopfe, Rachel Hill, Jane Lynch
    JNCI Monographs.2019; 2019(54): 132.     CrossRef
  • Steroid-induced diabetes in cancer patients
    Gemma Dinn
    Journal of Prescribing Practice.2019; 1(12): 610.     CrossRef
  • Risk Factors for Doxorubicin-Induced Serious Hyperglycaemia-Related Adverse Drug Reactions
    Jincheng Yang, Yu Wang, Kang Liu, Wen Yang, Jianying Zhang
    Diabetes Therapy.2019; 10(5): 1949.     CrossRef
  • Effect of glucose and palmitate environment on proliferation and migration of PC3‐prostate cancer cells
    Lívia Prometti Rezende, Maria Raquel Unterkircher Galheigo, Breno Costa Landim, Amanda Rodrigues Cruz, Françoise Vasconcelos Botelho, Renata Graciele Zanon, Rejane Maira Góes, Daniele Lisboa Ribeiro
    Cell Biology International.2019; 43(4): 373.     CrossRef
  • Incidence of Diabetes After Cancer Development
    Yul Hwangbo, Danbee Kang, Minwoong Kang, Saemina Kim, Eun Kyung Lee, Young Ae Kim, Yoon Jung Chang, Kui Son Choi, So-Youn Jung, Sang Myung Woo, Jin Seok Ahn, Sung Hoon Sim, Yun Soo Hong, Roberto Pastor-Barriuso, Eliseo Guallar, Eun Sook Lee, Sun-Young Kon
    JAMA Oncology.2018; 4(8): 1099.     CrossRef
Close layer
Characterization of Incidentally Detected Adrenal Pheochromocytoma.
Ye An Kim, Yul Hwangbo, Min Joo Kim, Hyung Jin Choi, Je Hyun Seo, Yenna Lee, Soo Heun Kwak, Eu Jeong Ku, Tae Jung Oh, Eun Roh, Jae Hyun Bae, Jung Hee Kim, Kyoung Soo Park, Seong Yeon Kim
Endocrinol Metab. 2012;27(2):132-137.   Published online June 20, 2012
DOI: https://doi.org/10.3803/EnM.2012.27.2.132
  • 2,172 View
  • 28 Download
  • 3 Crossref
AbstractAbstract PDF
BACKGROUND
In approach to an adrenal incidentaloma, early exclusion of pheochromocytoma is clinically important, due to the risk of catecholamine crisis. The aims of this study are to investigate the characteristics of incidentally detected pheochromocytomas, compared with that of the other adrenal incidentalomas, and to compare these characteristics with those of symptomatic pheochromocytomas. METHODS: In this retrospective study, we reviewed the medical records of 198 patients with adrenal incidentaloma from 2001 to 2010. We analyzed the clinical, laboratory and radiological data of pheochromocytomas, in comparison with those of the other adrenal incidentalomas. We also compared the characteristics of these incidentally detected pheochromocytomas with the medical records of 28 pathologically proven pheochromocytomas, diagnosed based on typical symptoms. RESULTS: Among the 198 patients with adrenal incidentaloma, nineteen patients were diagnosed with pheochromocytoma. Pheochromocytomas showed larger size and higher Hounsfield unit at precontrast computed tomography (CT) than did non-pheochromocytomas. All pheochromocytomas were larger than 2.0 cm, and the Hounsfield units were 19 or higher in precontrast CT. When both criteria of size > 2.0 cm and Hounsfield unit > 19 were met, the sensitivity and specificity for the diagnosis of pheochromocytoma were 100% and 79.3%, respectively. Compared with patients with pheochromocytoma, diagnosed based on typical symptoms, patients with incidentally detected pheochromocytoma were older, presented less often with hypertension, and showed lower levels of 24-hour urine metanephrine. CONCLUSION: Adrenal incidentaloma with < 2.0 cm in size or < or = 19 Hounsfield units in precontrast CT imaging was less likely to be a pheochromocytoma. Patients with incidentally discovered pheochromocytoma showed lower catecholamine metabolites, compared with those patients with symptomatic pheochromocytoma.

Citations

Citations to this article as recorded by  
  • Guidelines for the Management of Adrenal Incidentaloma: the Korean Endocrine Society, Committee of Clinical Practice Guidelines
    Jung-Min Lee, Mee Kyoung Kim, Seung-Hyun Ko, Jung-Min Koh, Bo-Yeon Kim, Sang-Wan Kim, Soo-Kyung Kim, Hae-Jin Kim, Ohk-Hyun Ryu, Juri Park, Jung-Soo Lim, Seong Yeon Kim, Young Kee Shong, Soon Jib Yoo
    The Korean Journal of Medicine.2017; 92(1): 4.     CrossRef
  • Clinical Guidelines for the Management of Adrenal Incidentaloma
    Jung-Min Lee, Mee Kyoung Kim, Seung-Hyun Ko, Jung-Min Koh, Bo-Yeon Kim, Sang Wan Kim, Soo-Kyung Kim, Hae Jin Kim, Ohk-Hyun Ryu, Juri Park, Jung Soo Lim, Seong Yeon Kim, Young Kee Shong, Soon Jib Yoo
    Endocrinology and Metabolism.2017; 32(2): 200.     CrossRef
  • Characterization of Incidentally Detected Adrenal Pheochromocytoma
    Soon Jib Yoo, Woohyeon Kim
    Endocrinology and Metabolism.2012; 27(2): 116.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism